What are the major opportunities in the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market? What are the strategies for the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market?

For detailed insights on the major opportunities and strategies in the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market, Read More

How does the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market relate to the overall economy and other similar markets?

For detailed insights on Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market growth? SWOT analysis of the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market.

For detailed insights on the key dynamics influencing the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market growth and SWOT analysis of the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs industry, Read More

Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages : 200

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report 2025

Name: Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drugs (Semaglutide, Liraglutide, Tirzepatide, Other Drugs), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Pharmacies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

• Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market size has reached to $13.38 billion in 2024

• Expected to grow to $28.3 billion in 2029 at a compound annual growth rate (CAGR) of 16.3%

• Growth Driver: Rising Prevalence Of Obesity Fueling The Growth Of The Market Due To Increasing Demand For Effective Weight Management Solutions

• Market Trend: Innovative GLP-1Based Therapies Driving Advances In Obesity Treatment

• North America was the largest region in 2024.

What Is Covered Under Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

Glucagon-like peptide (GLP)-1 agonists are medications that replicate the action of the GLP-1 hormone to help control blood sugar and reduce appetite. They boost insulin release, delay stomach emptying, and increase feelings of fullness. Initially designed for type 2 diabetes, they are now commonly used for weight management in overweight and obese patients.

The main drugs involved in glucagon-like peptide (GLP)-1 agonists weight loss drugs market are semaglutide, liraglutide, tirzepatide, and other drugs. Semaglutide, marketed as wegovy, is an injectable prescription medication designed to aid weight loss in adults with obesity or overweight conditions accompanied by weight-related health issues. The different routes of administration include parenteral and oral and are distributed through hospital pharmacies, retail pharmacies, and other pharmacies.

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size 2025 And Growth Rate?

The glucagon-like peptide (GLP) -1 agonists weight loss drugs market size has grown rapidly in recent years. It will grow from $13.38 billion in 2024 to $15.5 billion in 2025 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to the rising prevalence of obesity, increasing cases of type 2 diabetes, growing awareness of obesity-related health risks, rising healthcare expenditure, increasing focus on chronic disease management, and improved access to healthcare.

What Is The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Forecast?

The glucagon-like peptide (GLP) -1 agonists weight loss drugs market size is expected to see rapid growth in the next few years. It will grow to $28.3 billion in 2029 at a compound annual growth rate (CAGR) of 16.3%. The growth in the forecast period can be attributed to increasing demand for effective weight loss solutions, expansion of drug indications beyond diabetes, rising investments in research and development, growing adoption of personalized medicine, and increasing awareness through direct-to-consumer marketing. Major trends in the forecast period include the development of oral glucagon-like peptide (GLP)-1 formulations, advancements in sustained-release drug delivery, integration of digital health tools for monitoring, use of artificial intelligence in drug discovery and development, and innovation in peptide engineering for enhanced efficacy.

The forecast of 16.3% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of semaglutide and liraglutide sourced from Denmark and Austria, thereby limiting access to obesity treatments and elevating endocrinology medication expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmented?

1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs

2) By Route of Administration: Parenteral, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

Subsegments:

1) By Semaglutide: Ozempic, Wegovy, Rybelsus

2) By Liraglutide: Saxenda, Victoza

3) By Tirzepatide: Mounjaro, Zepbound

4) By Other Drugs: Exenatide, dulaglutide, Albiglutide, Efpeglenatide

What Is Driving The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market? Rising Prevalence Of Obesity Fueling The Growth Of The Market Due To Increasing Demand For Effective Weight Management Solutions

The rising prevalence of obesity is expected to propel the growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market going forward. Obesity refers to a medical condition characterized by excessive body fat accumulation that presents a risk to health. Obesity rates are growing due to unhealthy eating habits where people consume more fast food and sugary drinks, lacking proper nutrition and balance. As the number of individuals affected by obesity and its related complications continues to rise, the demand for effective treatment options is increasing, thereby driving the use of glucagon-like peptide (GLP-1) agonist weight loss drugs for their proven ability to support weight loss and enhance metabolic health. For instance, in March 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2022, one in eight people globally were living with obesity. Among the 2.5 billion overweight adults, approximately 890 million were classified as having obesity. Additionally, overall, 43% of the global adult population was overweight, with 16% falling into the obese category. Therefore, the rising prevalence of obesity is driving the growth of glucagon-like peptide (GLP)-1 agonist weight loss drugs market.

Who Are The Major Players In The Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

Major companies operating in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.

What Are The Key Trends Of The Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market? Innovative GLP-1Based Therapies Driving Advances In Obesity Treatment

Major companies operating in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are developing innovative obesity treatment solutions to enhance efficacy and improve patient outcomes. Obesity treatment solutions refer to therapies that mimic the GLP-1 hormone to regulate appetite, enhance satiety, and promote weight loss. These drugs help manage obesity by improving metabolic function and supporting long-term weight control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received US Food and Drug Administration approval for Zepbound, a medication for chronic weight management in adults with obesity or overweight who have related health conditions such as type 2 diabetes or sleep apnea. The drug works by activating GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic function.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market? Roche Acquires Carmot Therapeutics To Strengthen Obesity And Diabetes Drug Portfolio

In December 2023, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics for $2.7 billion. With this acquisition, Roche gains access to Carmot's pipeline of incretin-based therapies for obesity and diabetes, including dual GLP-1/GIP receptor agonists CT-388 and CT-868 and GLP-1 receptor agonist CT-996. Carmot Therapeutics Inc. is a US-based biotechnology company that focuses on developing disease-modifying therapies for metabolic diseases, such as obesity and diabetes.

What Is The Regional Outlook For The Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

The glucagon-like peptide (GLP)-1 agonists weight loss drugs market consists of sales of products such as dulaglutide (trulicity), exenatide (byetta, bydureon), and lixisenatide (adlyxin). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide (glp)-1 agonists weight loss drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$15.5 billion
Revenue Forecast In 2034	$28.3 billion
Growth Rate	CAGR of 16.3% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The glucagon-like peptide (GLP)-1 agonists weight loss drugs market covered in this report is segmented – 1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs 2) By Route of Administration: Parenteral, Oral 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies Subsegments: 1) By Semaglutide: Ozempic, Wegovy, Rybelsus 2) By Liraglutide: Saxenda, Victoza 3) By Tirzepatide: Mounjaro, Zepbound 4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Characteristics

3. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Trends And Strategies

4. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Rate Analysis

5.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Total Addressable Market (TAM)

6. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmentation

6.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Semaglutide

Liraglutide

Tirzepatide

Other Drugs

6.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Parenteral

Oral

6.3. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Other Pharmacies

6.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Semaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ozempic

Wegovy

Rybelsus

6.5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Saxenda

Victoza

6.6. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Tirzepatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Mounjaro

Zepbound

6.7. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Exenatide

Dulaglutide

Albiglutide

Efpeglenatide

7. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Regional And Country Analysis

7.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

8.1. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

9.1. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

9.2. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

10.1. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

11.1. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

11.2. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

12.1. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

13.1. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

14.1. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

14.2. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

15.1. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

15.2. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

16.1. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

17.1. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

18.1. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

19.1. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

20.1. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

21.1. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

21.2. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

22.1. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

23.1. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

23.2. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

24.1. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

24.2. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

25.1. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

25.2. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

26.1. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

26.2. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

27.1. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

28.1. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

28.2. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

29.1. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

29.2. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Landscape And Company Profiles

30.1. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Landscape

30.2. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Other Major And Innovative Companies

31.1. Novo Nordisk A/S

31.2. Teva Pharmaceutical Industries Ltd

31.3. Boehringer Ingelheim

31.4. Jiangsu Hengrui Medicine Co. Ltd

31.5. BioAge Labs

31.6. Hanmi Pharmaceutical

31.7. Innovent Biologics Inc.

31.8. Viking Therapeutics Inc.

31.9. Structure Therapeutics Inc.

31.10. Zealand Pharma A/S

31.11. Regor Therapeutics Inc.

31.12. I-Mab Biopharma (Shanghai) Co. Ltd.

31.13. Altimmune Inc.

31.14. TheracosBio LLC.

31.15. Oramed Pharmaceuticals

32. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

34. Recent Developments In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

35. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market High Potential Countries, Segments and Strategies

35.1 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Semaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Tirzepatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Pfizer Inc. Financial Performance

Table 79: Roche Holding AG Financial Performance

Table 80: Merck & Co. Inc Financial Performance

Table 81: Amgen Inc. Financial Performance

Table 82: Eli Lilly and Company Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Semaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Tirzepatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Pfizer Inc. Financial Performance

Figure 79: Roche Holding AG Financial Performance

Figure 80: Merck & Co. Inc Financial Performance

Figure 81: Amgen Inc. Financial Performance

Figure 82: Eli Lilly and Company Financial Performance

Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Glucagon-like Peptide 1 Global Market Report 2025 – By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users (Hospitals, Specialty Clinics...

Weight Loss Drugs Global Market Report 2025 – By Type (Liquid, Tablets, Capsules), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Weight-Reducing Aid, Fat Absorption Inhibi...

Peptide Based Metabolic Disorders Therapeutics Global Market Report 2025 – By Drug Type (Liraglutide, Exenatide, Other Drug Type), By Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Othe...

Peptide Therapeutics Global Market Report 2025 – By Type (Generic, Branded), By Route of Administration (Parenteral, Mucosal, Oral, Transdermal), By Application (Cancer, Cardiovascular Diseases, Central Nervous Systems, ...

Alpha Glucosidase Inhibitors Global Market Report 2025 – By Type (Dumping Syndrome, Type 2 Diabetes), By Drug class (Acarbose, Miglitol, Voglibose), By Constituent (Glucoamylase, Isomaltase, Maltase, Sucrase), By Distrib...

Weight Loss Supplements Global Market Report 2025 – By Type (Liquid, Powder, Softgels, Pills, Other Types), By Ingredients (Vitamins & Minerals, Amino Acids, Natural Extracts/Botanicals), By Distribution (Offline Channel...

Glucaric Acid Global Market Report 2025 – By Type (Calcium D-Glucarate, Pure Glucaric Acid, D-Glucaric Acid-1,4-Lactone, Potassium Sodium D-Glucarate, Other Types), By Application (Detergents, Healthcare, Food Manufactur...

Frequently Asked Questions

What is the definition of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market?

How will the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market drivers and restraints affect the market dynamics? What forces will shape the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs industry going forward?

The market major growth driver - Rising Prevalence Of Obesity Fueling The Growth Of The Market Due To Increasing Demand For Effective Weight Management Solutions. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market size has grown rapidly in recent years. It will grow from $13.38 billion in 2024 to $15.5 billion in 2025 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to the rising prevalence of obesity, increasing cases of type 2 diabetes, growing awareness of obesity-related health risks, rising healthcare expenditure, increasing focus on chronic disease management, and improved access to healthcare. The glucagon-like peptide (glp)-1 agonists weight loss drugs market size is expected to see rapid growth in the next few years. It will grow to " $28.3 billion in 2029 at a compound annual growth rate (CAGR) of 16.3%. The growth in the forecast period can be attributed to increasing demand for effective weight loss solutions, expansion of drug indications beyond diabetes, rising investments in research and development, growing adoption of personalized medicine, and increasing awareness through direct-to-consumer marketing. Major trends in the forecast period include the development of oral glucagon-like peptide (GLP)-1 formulations, advancements in sustained-release drug delivery, integration of digital health tools for monitoring, use of artificial intelligence in drug discovery and development, and innovation in peptide engineering for enhanced efficacy. For further insights on this market, request a sample here

How is the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market segmented?

The glucagon-like peptide (glp)-1 agonists weight loss drugsmarket covered in this report is segmented –
1) By Drugs: Semaglutide; Liraglutide; Tirzepatide; Other Drugs
2) By Route of Administration: Parenteral; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies Subsegments:
1) By Semaglutide: Ozempic; Wegovy; Rybelsus
2) By Liraglutide: Saxenda; Victoza
3) By Tirzepatide: Mounjaro; Zepbound
4) By Other Drugs: Exenatide; Dulaglutide; Albiglutide; Efpeglenatide For further insights on this market, request a sample here

Which region has the largest share of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market? What are the other regions covered in the report?

North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market?

What are the key trends in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market?

Major trends in this market include Innovative GLP-1Based Therapies Driving Advances In Obesity Treatment. For further insights on this market, request a sample here.